To test whether LNS8801 activates classical GPER signaling pathways in AML, we treated primary AML cells with LNS8801 and/or the GPER-specific antagonist G-36 (36) and looked for changes in cAMP-responsive element binding protein (CREB) phosphorylation, as CREB phosphorylation is a well-established downstream readout of GPER activation (32, 37, 38). The gene discussed is CREB1; the disease is acute myeloid leukemia.